Pharmeinsa SRL
1.0 FTEPharmeinsa reported total assets of 757,173 € at the end of the 2025 financial year (annual accounts filed with the NBB on 17 Mar 2026), with 1 full-time equivalent.
The score of Pharmeinsa shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -95 % Total assets +200 % Headcount (avg FTE) +67 %
Accounts of the company itself (not consolidated).
The full file covers 4 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharmeinsa's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 17 Mar 2026
- Year ended 31 Dec 2024filed on 20 Mar 2025
- Year ended 31 Dec 2023filed on 04 Apr 2024
- Year ended 31 Dec 2022filed on 13 Apr 2023
Pharmeinsa's financial analysis
- Solvency0.7%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharmeinsa
Pharmeinsa's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0787.352.463
- VAT number
- BE0787352463
- Peppol
- Registered · 0208:0787352463 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 16 Jun 2022
- Registered office
- 4780 Sankt Vith
- Size
- Micro · 1.0 FTE
- Latest accounts
- 2025 · filed on 17 Mar 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Pharmeinsa (SRL) has been based in Sankt Vith since 2022, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 146,188 € and equity of 5,042 €; its revenue is not published. With 1.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 0.7%, below the median of its sector (41.5%).
Companies similar to Pharmeinsa
Companies in the same business, of comparable size and area, outside its group.
- Apotheek De Vijzel Retail sale of pharmaceutical products Zoersel · balance sheet 509,493 €
- Marc Thoné Retail sale of pharmaceutical products Antwerp · balance sheet 93,815 €
- Biloba Heverlee Retail sale of pharmaceutical products Leuven · balance sheet 760,814 €
- HDfarma Retail sale of pharmaceutical products Zedelgem · balance sheet 779,162 €
- Pharmacie Flawinne Retail sale of pharmaceutical products Jodoigne · balance sheet 794,460 €
- Apo-M Retail sale of pharmaceutical products Kortenberg · balance sheet 852,674 €
- Anglopharma Retail sale of pharmaceutical products De Panne · balance sheet 669,817 €
- LES Pharmacies Lambrechts Retail sale of pharmaceutical products Molenbeek-Saint-Jean · balance sheet 896,725 €
Frequently asked questions about Pharmeinsa
What is the revenue of Pharmeinsa?
Pharmeinsa files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharmeinsa?
In Belgium, the VAT number is the company number prefixed with BE: BE0787352463 for Pharmeinsa, if the company is VAT-registered. Its company number (CBE) is 0787.352.463.
Where is the registered office of Pharmeinsa?
According to the CBE register, the registered office of Pharmeinsa is in 4780 Sankt Vith.
What is the equity of Pharmeinsa?
At the close of the 2025 financial year, the equity of Pharmeinsa amounts to 5,042 €, a solvency of 0.7% of total assets.
How many people work at Pharmeinsa?
1.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Pharmeinsa?
The register lists 1 active mandates at Pharmeinsa. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharmeinsa
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →